INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Grant or awardVerified data

McKinley Kate reported RANI

Chief Business Officer · Rani Therapeutics Holdings, Inc. · Rani Therapeutics Holdings, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
805.5K
Price
—
Executed
Jun 3, 2026
Disclosed
Jun 5, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 3 executedJun 5, 2026 disclosed

RANI · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RANI

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    JA
    Javadi AlirezaChief Technical Officer
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    805.5K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    IT
    Imran TalatDirector, Chief Executive Officer
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    3.80M sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BJ
    Bailey Vasudev JaiprakashDirector
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    123.6K sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BA
    Bassan AbrahamDirector
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    123.6K sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    9
    RA
    Rometty Lisa AnnDirector
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    123.6K sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001979211-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 3, 2026
    Published
    Jun 5, 2026
    Ingested by INSIDER
    Nov 5, 03:54 UTC
    Last re-read
    Nov 5, 03:54 UTC

    Extracted facts

    Filer
    McKinley Kate
    Role
    Chief Business Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Rani Therapeutics Holdings, Inc. — Stock Option (Right to Buy)
    Ticker
    RANI
    Shares
    805.5K
    Price per share
    $0
    Execution date (reported)
    Jun 3, 2026
    Owned after transaction
    805.5K shares
    Days from execution to publication
    2

    What this establishes

    McKinley Kate filed this Form 4 reporting a grant or award of RANI on Jun 3, 2026. It became public on Jun 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Business Officer
    McKinley Katecik:0001979211
    Issuer
    Rani Therapeutics Holdings, Inc.cik:0001856725

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.